TP53COR1

Summary

TP53COR1 (tumor protein p53 pathway corepressor 1, HGNC:43652) is a long non-coding RNA gene on chromosome 6p21.2.

Predicted to act upstream of or within negative regulation of gene expression. Predicted to be part of ribonucleoprotein complex.

Source: NCBI Gene 102800311 — RefSeq curated summary.

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43652
Approved symbol	TP53COR1
Name	tumor protein p53 pathway corepressor 1
Location	6p21.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	linc-p21, lincRNA-p21, Trp53cor1
OMIM	616343
Entrez	102800311

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 22)

• Our studies identify lincRNA-p21 as a novel regulator of cell proliferation and apoptosis and suggest that this lncRNA could serve as a therapeutic target to treat atherosclerosis and related cardiovascular disorders. (PMID:25156994)
• We propose that the mutation of a single p53 allele provides a pro-oncogenic function early in skin cancer development through a dominant inhibitory effect on UVB-induced lincRNA-p21 expression and the subsequent evasion of UVB-induced apoptosis. (PMID:25789975)
• Loss of lincRNA-p21 expression is associated with chronic lymphocytic leukemia. (PMID:25971364)
• Loss of lincRNA-p21 expression is associated with colorectal cancer. (PMID:26497997)
• G-A-A-G haplotype of lincRNA-p21 is associated with decreased risk of Coronary Artery Disease. (PMID:27340317)
• hLincRNA-p21 possesses inverted repeat Alu elements (IRAlus) in its mature, single exon functional isoforms. These IRAlu elements form structural domains that are conserved in primates and which regulate the cellular localization of hLincRNA-p21 over the course of the stress response. (PMID:27378782)
• data found that lincRNA-p21 expression was significantly downregulated during liver fibrosis (PMID:27610008)
• Our results demonstrated that the expression of lncRNA-p21 was repressed in osteosarcoma (OS) tissue; growth curves and the cell colony formation assay showed that lncRNA-p21 significantly inhibited the proliferation of OS cell lines (PMID:29136769)
• lncRNA-p21 promoted the apoptosis of chondrocytes in OA via acting as a sponge for miR-451. (PMID:30272288)
• LincRNA-p21 participates in thoracic aortic aneurysms (TAA) by regulating the proliferation and apoptosis of vascular smooth muscle cells through the activation of TGF-b1 signaling pathway. (PMID:30302790)
• Results demonstrated that linc-p21 expression level was downregulated in gastric cancer (GC) cells and tissues and its overexpression suppressed the GC cell growth, cell cycle, and migration as well as the radiosensitivity by regulating the beta-catenin signaling pathway. These data suggested that lincRNA-p21 acted as a tumor suppressor gene in the development of GC. (PMID:30484893)
• Study provides evidence for lincRNAp21 to inhibit the progression of NSCLC via direct targeting of a miR175p associated signaling pathway. Bioinformatics and luciferase reporter analysis results confirmed that miR175p is a direct target for lincRNAp21. (PMID:30535441)
• LincRNA-p21 is aberrantly upregulated in non-small cell lung cancer and inhibits cell apoptosis by decreasing PUMA expression. (PMID:30556447)
• lincRNA-p21 suppresses the bladder cancer cell growth through inhibiting glutaminase and glutamine catabolism. (PMID:30902882)
• Study found that lncRNA-p21 is highly expressed in the neuroendocrine prostate cancer (NEPC) patients derived xenograft tissues. Results from cell lines and human clinical sample surveys also revealed that lncRNA-p21 expression is up-regulated in NEPC and antiandrogen enzalutamide treatment could increase the lncRNA-p21 to induce the neuroendocrine differentiation. (PMID:31189930)
• Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia. (PMID:32468342)
• p53-Dependent LincRNA-p21 Protects Against Proliferation and Anti-apoptosis of Vascular Smooth Muscle Cells in Atherosclerosis by Upregulating SIRT7 via MicroRNA-17-5p. (PMID:33169349)
• Exosomal lncRNA-p21 derived from mesenchymal stem cells protects epithelial cells during LPS-induced acute lung injury by sponging miR-181. (PMID:33891698)
• Downregulation of long non-coding RNAs in patients with bipolar disorder. (PMID:35523833)
• Biophysical characterisation of human LincRNA-p21 sense and antisense Alu inverted repeats. (PMID:35639511)
• Reactive oxygen species-induced long intergenic noncoding RNA p21 accelerates abdominal aortic aneurysm formation by promoting secretary smooth muscle cell phenotypes. (PMID:36436251)
• Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy. (PMID:38864216)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

Disease associations

OMIM: gene MIM:616343 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 0 entries

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.